Biotin liposomes can be used to target cancer cells that overexpress biotin receptors, delivering drugs directly to the tumor site. This reduces the side effects associated with systemic distribution of cytotoxic drugs and improves the efficacy of the treatment by concentrating the therapeutic agent in the tumor environment.
Biotin liposomes are specialized liposomal formulations that include biotin on their surface. This biotinylation enables specific binding to avidin or streptavidin, enhancing targeted delivery to cells expressing biotin receptors. This specificity makes biotin liposomes highly effective for targeted therapeutic delivery, particularly in cancer treatment where precision is crucial.
Yes, biotin liposomes are versatile and can be employed in various biomedical applications including gene delivery, vaccine adjuvant systems, and diagnostic imaging. Their biotin modification allows for the conjugation of various biomolecules, which can be tailored for specific research or clinical needs.
Preparing biotin liposomes involves careful consideration of lipid composition, biotin conjugation, and encapsulation efficiency. Techniques such as thin-film hydration followed by extrusion or sonication are commonly used. Ensuring the correct biotin to lipid ratio and optimizing the encapsulation process are crucial for maintaining functional integrity and achieving desired targeting properties.
Biotin liposomes should be stored at controlled temperatures, typically 4°C, and protected from light to maintain their stability and prolong shelf life. It is important to prevent freeze-thaw cycles, which can disrupt the liposomal structure and affect their functional properties
Drawing depicting the ILPCR assay format
The study focuses on the development of an ultrasensitive quantitative antigen detection system called Immunoliposome-PCR (ILPCR). This innovative method employs biotin-labeled polyethylene glycol (PEG) phospholipid conjugates integrated into liposomes as detection reagents. The liposomes encapsulate reporter DNA and are coupled to a biotin-labeled secondary antibody via a NeutrAvidin bridge. This system enhances the sensitivity and specificity of antigen detection, enabling the accurate quantification of antigens at very low concentrations.
Experimental results demonstrate the effectiveness of the biotin liposome detection reagent. Liposomes, approximately 120 nm in diameter, each containing about 800 accessible biotin receptors and 220 encapsulated reporters, were utilized to quantify carcinoembryonic antigen (CEA) in human serum. The ILPCR assay exhibited a linear dose-response curve from 10^-10 M to 10^-16 M CEA, with a detection limit of 13 fg/mL. This sensitivity surpasses traditional clinical assays by 1,500 times. Additionally, the study highlights the assay's reproducibility and repeatability, with coefficient of variance values below 6% for repeatability and below 2% for reproducibility. The research underscores the potential of ILPCR as a highly sensitive and reliable method for antigen detection, providing significant advancements over conventional techniques.
He, J., Evers, D. L., et al. Immunoliposome-PCR: a generic ultrasensitive quantitative antigen detection system. Journal of nanobiotechnology. 2012, 10: 1-17. Under Open Access license CC BY 2.0, without modification.
Click the button below to contact us or submit your feedback about this product.
Online Inquiry